April 7, 2015 | Medical equipment giant Medtronic has invested $2 million in DreaMed Diabetes, an Israeli startup company that develops a new delivery system of insulin. DreaMed has signed an exclusive development and license agreement with Medtronic for the development and marketing of products incorporating DreaMed’s technology in Medtronic’s insulin pumps. DreaMed was founded in 2014 by Eran Atlas and Shahar Miller.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments